Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Allarity Therapeutics Inc <ALLR.OQ> expected to post a loss of 25 cents a share - Earnings Preview
Allarity Therapeutics Inc ALLR.OQ ALLR.O is expected to show no change in quarterly revenue when it reports results on August 15 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Allarity Therapeutics Inc is for a loss of 25 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Allarity Therapeutics Inc is $10.25, about 632.1% above its last closing price of $1.40
This summary was machine generated August 13 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic